{"title":"Dienogest治疗盆腔疼痛和性交困难的疗效:综合meta分析和系统评价","authors":"S. Sutrisno, Wildan Aulia Firdaus","doi":"10.55561/ajhr.v2i1.73","DOIUrl":null,"url":null,"abstract":"Introduction: Endometriosis is a severe disorder marked by endometrial tissue outside the uterus and linked to infertility, although typically manifesting as discomfort in the form of dysmenorrhea, dyspareunia, and pelvic pain. Dienogest is indicated as a first-line hormone treatment for endometriosis-related discomfort. The aim of this study is to analyze the efficacy of Dienogest on treating pelvic pain and dyspareunia compared to placebo or combined oral contraceptives (COC) in women with endometriosis.\nMethods: A systematic search is conducted in PubMed, ScienceDirect, and Google Scholar. The PRISMA 2020 rules were used to screen the articles that were obtained. For the review, studies that examined how using dienogest in improving endometriosis were exposed to were taken into consideration. In a meta-analysis utilizing a random-effects model, odds ratios with their 95% confidence intervals (CI) were provided.\nResults: Five studies that met the criteria for inclusion were determined to be pertinent to the association between using dienogest in improving endometriosis (n=711). The Dienogest group had substantially improve pelvic pain with a mean difference of 1.01 (95% CI 1.2, 0.82; p<0.00001) and dyspareunia with a mean difference of 0.58 (95% CI 1.09, 0.08; p=0.02) compared to placebo. Compared to combined oral contraceptives, COC had substantially improves dyspareunia with a mean difference of 0.99 (95% CI 0.62, 1.37; p<0.00001) and pelvic pain with a mean difference of 1.15 (95% CI 0.23, 0.83; p=0.01).\nConclusion: Dienogest should be considered as an alternate treatment for endometriosis-related symptoms. In double-blind research, DNG efficacy was compared to placebo.","PeriodicalId":8534,"journal":{"name":"Asian Journal of Pharmaceutical Research and Health Care","volume":"65 1","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Dienogest on Pelvic Pain and Dyspareunia: Comprehensive Meta-Analysis and Systematic Review\",\"authors\":\"S. Sutrisno, Wildan Aulia Firdaus\",\"doi\":\"10.55561/ajhr.v2i1.73\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Endometriosis is a severe disorder marked by endometrial tissue outside the uterus and linked to infertility, although typically manifesting as discomfort in the form of dysmenorrhea, dyspareunia, and pelvic pain. Dienogest is indicated as a first-line hormone treatment for endometriosis-related discomfort. The aim of this study is to analyze the efficacy of Dienogest on treating pelvic pain and dyspareunia compared to placebo or combined oral contraceptives (COC) in women with endometriosis.\\nMethods: A systematic search is conducted in PubMed, ScienceDirect, and Google Scholar. The PRISMA 2020 rules were used to screen the articles that were obtained. For the review, studies that examined how using dienogest in improving endometriosis were exposed to were taken into consideration. In a meta-analysis utilizing a random-effects model, odds ratios with their 95% confidence intervals (CI) were provided.\\nResults: Five studies that met the criteria for inclusion were determined to be pertinent to the association between using dienogest in improving endometriosis (n=711). The Dienogest group had substantially improve pelvic pain with a mean difference of 1.01 (95% CI 1.2, 0.82; p<0.00001) and dyspareunia with a mean difference of 0.58 (95% CI 1.09, 0.08; p=0.02) compared to placebo. Compared to combined oral contraceptives, COC had substantially improves dyspareunia with a mean difference of 0.99 (95% CI 0.62, 1.37; p<0.00001) and pelvic pain with a mean difference of 1.15 (95% CI 0.23, 0.83; p=0.01).\\nConclusion: Dienogest should be considered as an alternate treatment for endometriosis-related symptoms. In double-blind research, DNG efficacy was compared to placebo.\",\"PeriodicalId\":8534,\"journal\":{\"name\":\"Asian Journal of Pharmaceutical Research and Health Care\",\"volume\":\"65 1\",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Journal of Pharmaceutical Research and Health Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55561/ajhr.v2i1.73\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical Research and Health Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55561/ajhr.v2i1.73","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
简介:子宫内膜异位症是一种以子宫外子宫内膜组织为特征的严重疾病,与不孕有关,但通常表现为痛经、性交困难和盆腔疼痛等不适。Dienogest是子宫内膜异位症相关不适的一线激素治疗。本研究的目的是分析Dienogest治疗子宫内膜异位症女性盆腔疼痛和性交困难的疗效,并与安慰剂或联合口服避孕药(COC)进行比较。方法:系统检索PubMed、ScienceDirect和b谷歌Scholar。使用PRISMA 2020规则对获得的物品进行筛选。在这篇综述中,研究了如何使用dienogest来改善子宫内膜异位症的研究被考虑在内。在使用随机效应模型的荟萃分析中,提供了具有95%置信区间(CI)的优势比。结果:符合纳入标准的5项研究被确定与使用dienogest改善子宫内膜异位症相关(n=711)。Dienogest组明显改善了盆腔疼痛,平均差异为1.01 (95% CI 1.2, 0.82;p<0.00001)和性交困难,平均差异为0.58 (95% CI 1.09, 0.08;P =0.02)。与联合口服避孕药相比,COC显著改善了性交困难,平均差异为0.99 (95% CI 0.62, 1.37;p<0.00001)和盆腔疼痛,平均差异为1.15 (95% CI 0.23, 0.83;p = 0.01)。结论:Dienogest可作为子宫内膜异位症相关症状的替代治疗方法。在双盲研究中,将DNG疗效与安慰剂进行比较。
Efficacy of Dienogest on Pelvic Pain and Dyspareunia: Comprehensive Meta-Analysis and Systematic Review
Introduction: Endometriosis is a severe disorder marked by endometrial tissue outside the uterus and linked to infertility, although typically manifesting as discomfort in the form of dysmenorrhea, dyspareunia, and pelvic pain. Dienogest is indicated as a first-line hormone treatment for endometriosis-related discomfort. The aim of this study is to analyze the efficacy of Dienogest on treating pelvic pain and dyspareunia compared to placebo or combined oral contraceptives (COC) in women with endometriosis.
Methods: A systematic search is conducted in PubMed, ScienceDirect, and Google Scholar. The PRISMA 2020 rules were used to screen the articles that were obtained. For the review, studies that examined how using dienogest in improving endometriosis were exposed to were taken into consideration. In a meta-analysis utilizing a random-effects model, odds ratios with their 95% confidence intervals (CI) were provided.
Results: Five studies that met the criteria for inclusion were determined to be pertinent to the association between using dienogest in improving endometriosis (n=711). The Dienogest group had substantially improve pelvic pain with a mean difference of 1.01 (95% CI 1.2, 0.82; p<0.00001) and dyspareunia with a mean difference of 0.58 (95% CI 1.09, 0.08; p=0.02) compared to placebo. Compared to combined oral contraceptives, COC had substantially improves dyspareunia with a mean difference of 0.99 (95% CI 0.62, 1.37; p<0.00001) and pelvic pain with a mean difference of 1.15 (95% CI 0.23, 0.83; p=0.01).
Conclusion: Dienogest should be considered as an alternate treatment for endometriosis-related symptoms. In double-blind research, DNG efficacy was compared to placebo.